ZIOPHARM to Present at the 34th Annual J.P. Morgan Healthcare Conference


BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence J.N. Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th, 2016 at 1:30 p.m. PT at The Westin St. Francis in San Francisco, CA.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T), natural killer (NK) and T cell receptor (TCR) cell-based approaches that use viral and non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and more precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.


            

Contact Data